(Redirected from 17-hydroxyprogesterone)
Jump to navigation Jump to search
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
  • US: B (No risk in non-human studies)
  • B
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life10 days (17-OHPC)[1]
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass330.46
3D model (JSmol)
Melting point219.5 °C (427.1 °F)

WikiDoc Resources for 17-Hydroxyprogesterone


Most recent articles on 17-Hydroxyprogesterone

Most cited articles on 17-Hydroxyprogesterone

Review articles on 17-Hydroxyprogesterone

Articles on 17-Hydroxyprogesterone in N Eng J Med, Lancet, BMJ


Powerpoint slides on 17-Hydroxyprogesterone

Images of 17-Hydroxyprogesterone

Photos of 17-Hydroxyprogesterone

Podcasts & MP3s on 17-Hydroxyprogesterone

Videos on 17-Hydroxyprogesterone

Evidence Based Medicine

Cochrane Collaboration on 17-Hydroxyprogesterone

Bandolier on 17-Hydroxyprogesterone

TRIP on 17-Hydroxyprogesterone

Clinical Trials

Ongoing Trials on 17-Hydroxyprogesterone at Clinical Trials.gov

Trial results on 17-Hydroxyprogesterone

Clinical Trials on 17-Hydroxyprogesterone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on 17-Hydroxyprogesterone

NICE Guidance on 17-Hydroxyprogesterone


FDA on 17-Hydroxyprogesterone

CDC on 17-Hydroxyprogesterone


Books on 17-Hydroxyprogesterone


17-Hydroxyprogesterone in the news

Be alerted to news on 17-Hydroxyprogesterone

News trends on 17-Hydroxyprogesterone


Blogs on 17-Hydroxyprogesterone


Definitions of 17-Hydroxyprogesterone

Patient Resources / Community

Patient resources on 17-Hydroxyprogesterone

Discussion groups on 17-Hydroxyprogesterone

Patient Handouts on 17-Hydroxyprogesterone

Directions to Hospitals Treating 17-Hydroxyprogesterone

Risk calculators and risk factors for 17-Hydroxyprogesterone

Healthcare Provider Resources

Symptoms of 17-Hydroxyprogesterone

Causes & Risk Factors for 17-Hydroxyprogesterone

Diagnostic studies for 17-Hydroxyprogesterone

Treatment of 17-Hydroxyprogesterone

Continuing Medical Education (CME)

CME Programs on 17-Hydroxyprogesterone


17-Hydroxyprogesterone en Espanol

17-Hydroxyprogesterone en Francais


17-Hydroxyprogesterone in the Marketplace

Patents on 17-Hydroxyprogesterone

Experimental / Informatics

List of terms related to 17-Hydroxyprogesterone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


17-Hydroxyprogesterone (17-OHP) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.


It is derived from progesterone via 17-hydroxylase, a P450c17 enzyme, or from 17-hydroxypregnenolone via 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase.

17-OHP increases in the third trimester of pregnancy primarily due to fetal adrenal production.

This steroid is primarily produced in the adrenal glands and to some degree in the gonads, specifically the corpus luteum of the ovary. Normal levels are 3-90 ng/dl in children, and in women, 20-100 ng/dl prior to ovulation, and 100-500 ng/dl during the luteal phase.[2][3]

17-Hydroxyprogesterone caproate

17-OHP is not the same compound as 17-hydroxyprogesterone caproate (17-OHPC), the latter being the caproic acid of 17-hydroxyprogesterone that was first clinically introduced as an injectable version of the steroid under the name of Delalutin in 1956.

The use of 17-OHPC in pregnancy to prevent preterm birth has a long history. A 2006 Cochrane Review concluded "...important maternal and infant outcomes have been poorly reported to date... information regarding the potential harms of progesterone therapy to prevent preterm birth is limited".[4] There was a similar conclusion from a review by Marc Keirse.[5] Three clinical studies of 250 mg/week of i.m. 17-OHPC showed a trend for an increase in pregnancy loss due to miscarriage compared to placebo.[6][7][8][9] There had been speculation that the castor oil in some 17-OHPC formulations may not be beneficial for pregnancy.[10][11]

In contrast, a large NIH study in 2003 looked at the effect of 17-OHPC injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls.[12]

A follow-up study of the offspring showed no evidence that 17-OHPC affected the children in the first years of life.[13] Based on these NIH data, 17 OHPC was approved by the FDA in 2011 as a drug to reduce the risk of premature birth in selected patients at risk. (v.i.)

17-OHPC is a category B drug according to the FDA.

Clinical use


Measurements of levels of 17-OHP are useful in the evaluation of patients with suspected congenital adrenal hyperplasia as the typical enzymes that are defective, namely 21-hydroxylase and 11β-hydroxylase, lead to a build-up of 17-OHP. In contrast, the rare patient with 17α-hydroxylase deficiency will have very low or undetectable levels of 17-OHP. 17-OHP levels can also be used to measure contribution of progestational activity of the corpus luteum during pregnancy as progesterone but not 17-OHP is also contributed by the placenta.


17-OHPC was first introduced in 1956 as Delalutin to reduce pregnancy loss. After decades of use, Squibb, the manufacturer, voluntarily withdrew the brand, however, physicians continued to use 17-OHPC "off label". Renewed interest was sparked with a large NIH-sponsored study in 2003 that found that 17-OHPC reduced the risk of premature birth in selected at-risk pregnant women.[12] With follow-up data showing no evidence of harmful effects on the offspring, the FDA approved the drug, as sponsored by KV Pharmaceutical as Makena, as an orphan drug in February 2011 to reduce the risk of premature birth in women prior to 37 weeks gestation with a single fetus who had at least one previous premature birth.[14] The drug is not effective in preventing premature birth in women with multiples. With the arrival of Makena as an orphan drug, the price of the drug was to increase from $15 to $1,500 per dose meaning a typical treatment would cost $25–30,000, - a pricing strategy that was strongly criticized. The FDA then announced that pharmacies could continue to compound the drug at their usual cost of $10~20 per dose without fear of legal reprisals.,[15] and KV reduced its price to $690 per dose.[16]

17-Hydroxyprogesterone (17-OH-Prog in the diagram) may arise from either of two steroid precursors.


Earlier immunoassays like RIA (radioimmunoassay) or IRMA (immunoradiometric assay) were used to clinically determine 17-Hydroxyprogesterone. Today more sophisticated methods use gas or liquid chromatography and mass spectrometry (e.g. LC-MS/MS).

Additional images


Hydroxyprogesterone synthesis:[17] U.S. Patent 2,802,839

See also


  1. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
  2. Reference Values During Pregnancy
  3. normal ranges for hormone tests in women
  4. Dodd JM, Flenady V, Cincotta R, Crowther CA; The Cochrane Database of Systematic Reviews 2006 Issue 1
  5. Keirse MJNC. Progesterone and Preterm: Seventy Years of "Deja vu" or "Still To Be Seen"?. Birth, 2004 September; 31:3.
  6. Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. NEJM 1975 October. 293(14):675.
  7. Yemini M, Borenstein R, Dreazen, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151(5):574-7.
  8. Meis PJ et al. Prevention of Recurrent Preterm Delivery by 17 Alpha-hydroxyprogesterone Caproate. NEJM, 2003: vol 348, no 24, pg 2379-2385.
  9. Keirse MJNC, Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990 February; 97:149.
  10. Duke University Medical Center, New England Journal of Medicine, correspondence, vol 349.
  11. Hauth JC, Gilstrap LC, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 1983 May; 146(2): 187.
  12. 12.0 12.1 Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. (2003). "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate". N Engl J Med. 348 (24): 2379–85. doi:10.1056/NEJMoa035140. PMID 12802023.
  13. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast JA, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. (2007). "Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo". Obstet Gynecol. 110 (4): 865–72. doi:10.1097/01.AOG.0000281348.51499.bc. PMID 17906021.
  14. FDA press release regarding Makena approval
  15. http://www.macleans.ca/article.jsp?content=w6411446
  16. "Price of preterm birth medicine cut". Boston.com. Associated Press. April 2, 2011. Retrieved April 2, 2011.
  17. Template:Cite doi

External links